BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15674500)

  • 21. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two cases of complete response after imatinib mesylate treatment of advanced GIST.
    Papaxoinis G; Nikolaou M; Lianos E; Gaglia A; Economopoulos T; Pectasides D
    Anticancer Res; 2006; 26(6C):4869-72. PubMed ID: 17214353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J; Wang Y; Hou M; Li HY; Zhang J
    Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A gastric stromal tumor (GIST) with a prolonged partial response to a reduced dose of imatinib mesilate].
    Nakatani K; Tanabe S; Nishimura K; Shimoda T; Azuma M; Katada C; Sasaki T; Higuchi K; Koizumi W; Saigenji K
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):997-1000. PubMed ID: 16835496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
    Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
    Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A metastatic case of gastrointestinal stromal tumor (GIST) treated with imatinib mesylate (Glivec(®)) in Mali.
    Diallo DA; Ly M; Diallo G; Dembélé AK; Touré M; Touré BA; Koné A; Sidibé S; Dembelé M; Traore BC
    Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):675-7. PubMed ID: 21641899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
    Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
    Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
    Hsiao HH; Liu YC; Tsai HJ; Chen LT; Lee CP; Chuan CH; Wang JY; Yang SF; Tseng YT; Lin SF
    Kaohsiung J Med Sci; 2006 Dec; 22(12):599-603. PubMed ID: 17116620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib in gastrointestinal stromal tumors.
    Bakshi CA; Jain RA; Sastry PS; Sainani AR; Advani SH
    J Assoc Physicians India; 2004 May; 52():403-9. PubMed ID: 15656032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of recurrent gastrointestinal stromal tumor with complete response from treatment with reduced dose of imatinib mesylate].
    Toyokawa T; Yamashita Y; Yamamoto A; Shimizu S; Inoue T; Ikehara T; Sakashita K; Kanehara I; Teraoka H; Nishiguchi Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1723-5. PubMed ID: 23152028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor.
    Sawaki A; Ohashi K; Yamao K; Inada K; Shimizu Y; Matsuura A; Nakamura T; Suzuki T; Hara K; Okubo K; Ohno R
    J Gastroenterol; 2003; 38(7):690-4. PubMed ID: 12898363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.
    Saad Aldin E; Mourad F; Tfayli A
    Jpn J Clin Oncol; 2012 May; 42(5):447-50. PubMed ID: 22422898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A patient with metastatic gastrointestinal stromal tumor who responded to STI571].
    Terashima M; Abe K; Takeda Y; Saito K; Uesugi N; Kato K; Sato K; Maekawa T
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):607-10. PubMed ID: 11977548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Two cases of postoperative recurrence of gastric GIST treated by imatinib].
    Kikuchi H; Konn H; Kamiya K; Baba M; Ohta M; Kondo K; Hiramatsu Y; Yamamoto M; Tanaka T; Sugimura H; Ohashi M; Kanda T; Nakamura S
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1569-73. PubMed ID: 15508453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively].
    Okuda H; Tanaka H; Ueno M; Shitani M; Nasuno M; Suzuki C; Nishimura S; Kimura H; Yonezawa K; Abe T; Yoshida Y; Kawabata M
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1941-4. PubMed ID: 16282731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.
    Boruban C; Sencan O; Akmansu M; Atik ET; Ozbek S
    Anticancer Drugs; 2007 Sep; 18(8):969-72. PubMed ID: 17667604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.